Research Papers
This database includes peer-reviewed publications authored or funded by TB Alliance. Use the tags on the right to filter by subject, or search for a particular author or term using the search bar.
Displaying 186 papers
Tuberculosis
10/2016 - Tuberculosis.Nature Reviews Disease Primers. 2016/10/27/online. 16076. Macmillan Publishers Limited. http://dx.doi.org/10.1038/nrdp.2016.76
Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fl uoroquinolones: results from a multicountry surveillance project
7/2016 - Zignol, Matteo, Anna Dean, and Natavan Alikhanova. "Population-based Resistance of Mycobacterium Tuberculosis." The Lancet (Published Online July 7, 2016 Http://dx.doi.org/10.1016/S1473-3099(16)30190-6):
Developing a Framework for Evaluating Ethical Outcomes of Good Participatory Practices in TB Clinical Drug Trials
6/2016 - Journal of Empirical Research on Human Research Ethics 1556264616657452, first published on June 30, 2016 doi:10.1177/1556264616657452
Global burden of drug-resistant tuberculosis in children: a mathematical modelling study
6/2016 - Peter J Dodd, Charalambos Sismanidis, James A Seddon. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. The Lancet Infectious Diseases , Volume 0 , Issue 0
Grand Convergence: Aligning Technologies & Realities in Global Health
3/2016 - Yamey G, Morel C. Investing in Health Innovation: A Cornerstone to Achieving Global Health Convergence. PLOS Biology. 2016 Mar 1;14(3). doi: 10.1371/journal.pbio.1002389.
The Zika Loopholes: The FDA has a smart-sounding program to drive research for neglected diseases—with two big flaws
3/2016 - Brock WR, Cohen R, Cone J, McKenna L. The Zika Loopholes: The FDA.... March 25, 2016. http://www.politico.com/agenda/story/2016/03/the-right-way-to-encourage-companies-to-develop-a-treatment-for-zika-000079. Accessed March 25, 2016.
"Understanding and addressing the tuberculosis case detection gap national inventory studies to improve estimates of incidence and strengthen surveillance" with comments
3/2016 - Sismanidis C, Glaziou P, Bloss E, et. al. "Understanding and addressing the tuberculosis case detection gap national inventory studies to improve estimates of incidence and strengthen surveillance" with comments. 2016 Mar
Understanding and addressing the tuberculosis case detection gap national inventory studies to improve estimates of incidence and strengthen surveillance
3/2016 - Sismanidis C, Glaziou P, Bloss E, et. al. Understanding and addressing the tuberculosis case detection gap national inventory studies to improve estimates of incidence and strengthen surveillance. 2016 Mar.
Investing in Health Innovation: A Cornerstone to Achieving Global Health Convergence
3/2016 - Yamey G, Morel C. Investing in Health Innovation: A Cornerstone to Achieving Global Health Convergence. PLOS Biology. 2016 Mar 1;14(3). doi: 10.1371/journal.pbio.1002389.
Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults
3/2016 - Furin J., Alirol E, Allen E, et. al. Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults. Int J Tuberc Lung Dis. 20161 Mar; 20(3): 290-294.
Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials
3/2016 - Phillips PPJ, Mendel CM, Burger DA, et al. Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials. BMC Medicine. 2016 Mar.14:19. doi: 10.1186/s12916-016-0565-y
The pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in infants dosed at revised WHO-recommended treatment guidelines
1/2016 - Bekker A, Schaaf HS, Murray S, et. al. The pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in infants... Antimicrob Agents Chemother. 2016 Jan 25. pii: AAC.02600-15. doi: 10.1128/aac.02600-15.
The procurement landscape of pediatric tuberculosis treatment: a Global Drug Facility perspective
12/2015 - Scott C, Gardiner E, de Lucia A. The procurement landscape of pediatric tuberculosis treatment: a Global Drug Facility perspective. Int J Tuberc Lung Dis. 2015 Dec;19 Suppl 1:17-22. doi: 10.5588/ijtld.15.0478.
Pediatric tuberculosis drug market: an insider perspective on challenges and solutions
12/2015 - Usherenko I, Basu Roy U, Mazlish S, et. al. Pediatric tuberculosis drug market: an insider perspective on challenges and solutions. Int J Tuberc Lung Dis. 2015 Dec;19 Suppl 1:23-31. doi: 10.5588/ijtld.15.0479.
Paediatric formulations of second-line anti-tuberculosis medications: challenges and considerations
12/2015 - Taneja R, Garcia-Prats AJ, Furin J, Maheshwari HK. Paediatric formulations of second-line anti-tuberculosis medications: challenges and considerations. Int J Tuberc Lung Dis. 2015 Dec;19 Suppl 1:61-8. doi: 10.5588/ijtld.15.0435.
From availability to uptake: planning for the introduction of new, child-friendly anti-tuberculosis formulations
12/2015 - Malhotra S, Ursu I, Ghoneim R, et. al. From availability to uptake: planning for the introduction of new, child-friendly anti-tuberculosis formulations. Int J Tuberc Lung Dis. 2015 Dec;19 Suppl 1:32-8. doi: 10.5588/ijtld.15.0482.
Accelerating clinical drug development for children with tuberculosis
12/2015 - Murray S, McKenna L, Pelfrene E, Botgros R. Accelerating clinical drug development for children with tuberculosis. Int J Tuberc Lung Dis. 2015 Dec;19 Suppl 1:69-74. doi: 10.5588/ijtld.15.0616.
Towards early inclusion of children in tuberculosis drugs trials: a consensus statement
5/2015 - Nachman S, Ahmed A, Amanullah, et. al. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. Lancet Infect Dis. 2015 Jun;15(6):711-20. doi: 10.1016/S1473-3099(15)00007-9.
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant...
5/2015 - Dawson R, Diacon AH, Everitt D, et. al. Efficiency and safety of.... Lancet. 2015 May 2;385(9979):1738-47. doi: 10.1016/S0140-6736(14)62002-X.
Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models
4/2015 - Li SY, Irwin SM, Converse PJ, Mdluli KE, Lenaerts AJ, Nuermberger EL. Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models. Antimicrob Agents Chemother. 2015 Jul;59(7):4026-30. doi: 10.1128/AAC.00105-15.